A visionary team of venture capitalists and financial experts, frustrated by the fragmented state of fund management operations, took matters into their own hands. Today, they announce the launch of ...

Yet all this is some 3,500 miles away from the UK—and less than an hour’s drive from Manhattan—in Somerset County, New Jersey ...

Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...

Merck (MRK) closed at $115.86 in the latest trading session, marking a +0.53% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.54% for the day. Meanwhile ...

RAHWAY, N.J., September 11, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

They had seen a potential 2025 regulatory submission of its melanoma vaccine candidate with Merck as a key source of upside for the stock, but now the FDA says it doesn’t support Moderna filing ...

Paving the way for revolutionary, psychologically conscious approaches to estate planning, Paul Hood stands as a national ...